The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
RX 3117: Activity of an oral antimetabolite nucleoside in subjects with pancreatic cancer–Preliminary results of stage II of the phase Ia/IIb study.
 
Vincent M. Chung
Consulting or Advisory Role - Celgene; Perthera
Speakers' Bureau - Celgene
Research Funding - Novartis (Inst)
Travel, Accommodations, Expenses - Celgene
 
Jaime R. Merchan
No Relationships to Disclose
 
Allyson J. Ocean
No Relationships to Disclose
 
Drew W. Rasco
Employment - START
Consulting or Advisory Role - TaiRx, Inc.
Research Funding - Aeglea Biotherapeutics (Inst); Asana Biosciences (Inst); Bayer (Inst); Celgene (Inst); Eisai (Inst); Five Prime Therapeutics (Inst); Millennium (Inst); Pharmacyclics (Inst); Rexahn Pharmaceuticals (Inst); Santa Maria Biotherapeutics (Inst)
 
Hani M. Babiker
Consulting or Advisory Role - Celgene; Endocyte
 
Ira Oliff
No Relationships to Disclose
 
Ravi Kumar Paluri
No Relationships to Disclose
 
Eloy Roman
No Relationships to Disclose
 
Julie Poore
Employment - Rexahn Pharmaceuticals
Other Relationship - Rexahn Pharmaceuticals
 
Ely Benaim
Employment - Rexahn Pharmaceuticals
Leadership - Rexahn Pharmaceuticals
Stock and Other Ownership Interests - Rexahn Pharmaceuticals
Honoraria - Rexahn Pharmaceuticals